DASSAULT SYSTEMES SA ADR - DASTY STOCK NEWS

Dassault Systèmes reported the number of outstanding shares and voting rights as of June 30, 2022. The total number of outstanding shares stands at 1,333,800,851, while the total number of voting rights is 1,999,807,399. This data complies with the regulations set by the Autorité des marchés financiers. The calculation of voting rights includes shares with suspended voting rights, as intended by the regulatory framework. Shareholders are encouraged to declare crossing of thresholds to the company's Investor Relations.

Dassault Systèmes has disclosed its share repurchase activities from June 14 to June 17, 2022. The program, authorized by the General Meeting on May 19, 2022, involves purchasing ordinary shares to enhance shareholder value. Notably, the company acquired a total of 270,000 shares at an average price of €33.98 on June 14, 2022. The trades were executed across multiple markets including XPAR and DXE, with significant volumes reported on different days. For detailed transaction information, visit Dassault Systèmes' investor relations page.

eClinical Solutions is enhancing its role in the life sciences sector by participating in the DIA 2022 Global Annual Meeting in Chicago, where Katrina Rice will present on the evolution of clinical data roles. The session, titled 'Transformation of the Data Manager to the Data Scientist,' will focus on digitally-enabled processes to improve clinical trials. The company will also showcase advancements in its elluminate Clinical Data Cloud, aimed at streamlining data management and enhancing trial efficiency.

Dassault Systèmes announced a share repurchase program initiated by the General Meeting of Shareholders on May 19, 2022. The disclosure covers trading details for June 10, 2022, with a total of 162,000 shares acquired at an average price of €37.4235. Additional transactions accounted for 80,000 and 8,000 shares at average prices of €37.3774 and €37.4048, respectively. This buyback initiative aims to enhance shareholder value and reflects the company's commitment to returning capital to investors.

Dassault Systèmes held its 2022 Capital Markets Day on June 16, 2022, outlining its trajectory to achieve non-IFRS EPS objectives of €1.20 by 2024. Executive management emphasized the company’s strong position in the market, projecting growth across manufacturing, life sciences, and infrastructure sectors. The integration of Medidata diversifies opportunities, addressing a market potential of €100 billion. The firm reported a high cash conversion rate, achieving its deleveraging target ahead of schedule, ensuring financial flexibility for strategic priorities.

Dassault Systèmes disclosed its share repurchase activity for the period from June 1 to June 8, 2022. The program, approved at the General Meeting of Shareholders on May 19, 2022, involved trading in ordinary shares. On June 1 alone, 122,500 shares were bought at an average price of €38.9450. The company reported daily trading volumes and acquisition prices, indicating ongoing commitment to shareholder value. Detailed transaction information is available on their website.

Dassault Systèmes has disclosed its total outstanding shares and voting rights as of May 31, 2022. The company reported 1,333,390,823 outstanding shares, which correspond to 1,998,822,086 voting rights. This announcement complies with the regulations set forth by the Autorité des marchés financiers. Shareholders are advised to refer to the relevant articles for declaring any threshold crossings.

For further inquiries, shareholders can contact the Investor Relations Service at Dassault Systèmes.

On June 2, 2022, Dassault Systèmes disclosed its trading activities in own shares following the repurchase program approved by shareholders on May 19, 2022. This includes transactions from May 25 to May 31, 2022, highlighting daily trading volumes and weighted average acquisition prices for the shares, with notable transactions reported on May 25, which saw a total volume of 73,508 shares at an average price of €37.4488. Detailed insights into the transactions can be accessed via Dassault's investor relations website.

physIQ has announced two key appointments to its executive team to enhance its commercialization strategy. John Wilson is now Senior VP and GM of Life Sciences, focusing on customer initiatives and growth. Chris Englerth joins as VP of Marketing, leading marketing efforts to boost brand awareness. These changes aim to strengthen physIQ’s presence in the healthcare market, leveraging its FDA-cleared AI technology for better health outcomes and cost reductions.